• Average sales price per share was over 10% higher than the June 2025 public offering price SHELTON, Conn., Aug. 4, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or ...
SHELTON, Conn., June 30, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company focused on the discovery and development ...
Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results